The importance of the false-negative rate to validate a staging protocol for non-small cell lung cancer

First of all, we would like to congratulate Dr. Verdial et al. for their recently published article entitled “A prediction model for nodal disease among patients with non-small cell lung cancer” (1). Dr. Verdial and co-workers have analyzed their experience in mediastinal nodal staging for non-small cell lung cancer (NSCLC), based on the recommendations of the current guidelines, in order to find out a better model to predict nodal disease and reduce the need of invasive staging procedures.